{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T09:57:48Z","timestamp":1778234268163,"version":"3.51.4"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG047812"],"award-info":[{"award-number":["AG047812"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG060767"],"award-info":[{"award-number":["AG060767"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG066347"],"award-info":[{"award-number":["AG066347"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG069333"],"award-info":[{"award-number":["AG069333"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG079264"],"award-info":[{"award-number":["AG079264"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS205473"],"award-info":[{"award-number":["NS205473"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["\u2013 AG042178"],"award-info":[{"award-number":["\u2013 AG042178"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007131","name":"Texas Tech University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007131","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016183","name":"Garrison Family Foundation","doi-asserted-by":"publisher","award":["AG063162"],"award-info":[{"award-number":["AG063162"]}],"id":[{"id":"10.13039\/100016183","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016183","name":"Garrison Family Foundation","doi-asserted-by":"publisher","award":["AG071560"],"award-info":[{"award-number":["AG071560"]}],"id":[{"id":"10.13039\/100016183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.bbadis.2023.166942","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T16:55:26Z","timestamp":1699116926000},"page":"166942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Protective effects of SSRI, Citalopram in mutant APP and mutant Tau expressed dorsal raphe neurons in Alzheimer's disease"],"prefix":"10.1016","volume":"1870","author":[{"given":"Neha","family":"Sawant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudhir","family":"Kshirsagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Hemachandra","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arubala P.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2023.166942_bb0005","first-page":"91","article-title":"Depression and Alzheimer\u2019s disease, depress","volume":"8","author":"Tune","year":"1998","journal-title":"Anxiety"},{"key":"10.1016\/j.bbadis.2023.166942_bb0010","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1021\/acschemneuro.5b00135","article-title":"Serotonin: a new hope in Alzheimer\u2019s disease?","volume":"6","author":"Claeysen","year":"2015","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.bbadis.2023.166942_bb0015","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.neubiorev.2015.06.005","article-title":"When ageing meets the blues: are current antidepressants effective in depressed aged patients?","volume":"55","author":"Felice","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.bbadis.2023.166942_bb0020","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3389\/fphar.2019.01067","article-title":"Pharmacological treatment of depression in Alzheimer\u2019s disease: a challenging task","volume":"10","author":"Cassano","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbadis.2023.166942_bb0025","doi-asserted-by":"crossref","first-page":"14968","DOI":"10.1073\/pnas.1107411108","article-title":"Serotonin signaling is associated with lower amyloid-\u03b2 levels and plaques in transgenic mice and humans","volume":"108","author":"Cirrito","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2023.166942_bb0030","doi-asserted-by":"crossref","first-page":"e2666","DOI":"10.1212\/WNL.0000000000010733","article-title":"Effect of escitalopram on A\u03b2 levels and plaque load in an Alzheimer mouse model","volume":"95","author":"Cirrito","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2023.166942_bb0035","doi-asserted-by":"crossref","first-page":"e2658","DOI":"10.1212\/WNL.0000000000010725","article-title":"Effect of escitalopram dose and treatment duration on CSF A\u03b2 levels in healthy older adults: a controlled clinical trial","volume":"95","author":"Sheline","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2023.166942_bb0040","first-page":"236re4","article-title":"An antidepressant decreases CSF A\u03b2 production in healthy individuals and in transgenic AD mice","volume":"6","author":"Sheline","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbadis.2023.166942_bb0045","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.expneurol.2007.01.037","article-title":"Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice","volume":"205","author":"Nelson","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbadis.2023.166942_bb0050","doi-asserted-by":"crossref","first-page":"672","DOI":"10.2174\/1567205011666140812114715","article-title":"Fluoxetine improves behavioral performance by suppressing the production of soluble \u03b2-amyloid in APP\/PS1 mice","volume":"11","author":"Wang","year":"2014","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.bbadis.2023.166942_bb0055","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jad.2017.12.010","article-title":"HTR1A\/1B DNA methylation may predict escitalopram treatment response in depressed Chinese Han patients","volume":"228","author":"Wang","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bbadis.2023.166942_bb0060","doi-asserted-by":"crossref","first-page":"13328","DOI":"10.18632\/oncotarget.7798","article-title":"Escitalopram attenuates \u03b2-amyloid-induced tau hyperphosphorylation in primary hippocampal neurons through the 5-HT1A receptor mediated Akt\/GSK-3\u03b2 pathway","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbadis.2023.166942_bb0065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neurobiolaging.2018.03.011","article-title":"Escitalopram alleviates stress-induced Alzheimer\u2019s disease-like tau pathologies and cognitive deficits by reducing hypothalamic-pituitary-adrenal axis reactivity and insulin\/GSK-3\u03b2 signal pathway activity","volume":"67","author":"Wu","year":"2018","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbadis.2023.166942_bb0070","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12031-015-0519-4","article-title":"Escitalopram ameliorates forskolin-induced Tau hyperphosphorylation in HEK239\/tau441 cells","volume":"56","author":"Ren","year":"2015","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.bbadis.2023.166942_bb0075","doi-asserted-by":"crossref","first-page":"10056","DOI":"10.1038\/s41598-019-46558-1","article-title":"Escitalopram ameliorates cognitive impairment in D-galactose-injected ovariectomized rats: modulation of JNK, GSK-3\u03b2, and ERK signalling pathways","volume":"9","author":"Ibrahim","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2023.166942_bb0080","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.neuropharm.2012.10.002","article-title":"A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression?","volume":"67","author":"Walker","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbadis.2023.166942_bb0085","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/hmg\/ddab091","article-title":"Selective serotonin reuptake inhibitor citalopram ameliorates cognitive decline and protects against amyloid beta-induced mitochondrial dynamics, biogenesis, autophagy, mitophagy and synaptic toxicities in a mouse model of Alzheimer's disease","volume":"30","author":"Reddy","year":"2021","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2023.166942_bb0090","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/hmg\/ddab054","article-title":"Protective effects of antidepressant citalopram against abnormal APP processing and amyloid beta-induced mitochondrial dynamics, biogenesis, mitophagy and synaptic toxicities in Alzheimer's disease","volume":"30","author":"Reddy","year":"2021","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2023.166942_bb0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3233\/JAD-143012","article-title":"Escitalopram ameliorates tau hyperphosphorylation and spatial memory deficits induced by protein kinase a activation in Sprague Dawley rats","volume":"47","author":"Ren","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbadis.2023.166942_bb0100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12031-014-0475-4","article-title":"Citalopram attenuates tau hyperphosphorylation and spatial memory deficit induced by social isolation rearing in middle-aged rats","volume":"56","author":"Ren","year":"2015","journal-title":"Mol. Neurosci."},{"key":"10.1016\/j.bbadis.2023.166942_bb0105","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1152\/physrev.1992.72.1.165","article-title":"Structure and function of the brain serotonin system","volume":"72","author":"Jacobs","year":"1992","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bbadis.2023.166942_bb0110","first-page":"907","article-title":"Selective serotonin reuptake inhibitors pathway, Pharmacogenet","volume":"19","author":"Sangkuhl","year":"2009","journal-title":"Genomics"},{"key":"10.1016\/j.bbadis.2023.166942_bb0115","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3389\/fendo.2019.00158","article-title":"Tryptophan metabolic pathways and brain serotonergic activity: a comparative review","volume":"(Lausanne)10","author":"H\u00f6glund","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bbadis.2023.166942_bb0120","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jchemneu.2003.10.002","article-title":"The human raphe nuclei and the serotonergic system","volume":"26","author":"Hornung","year":"2003","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.bbadis.2023.166942_bb0125","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0165-0327(98)00221-3","article-title":"Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects","volume":"51","author":"Stahl","year":"1998","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bbadis.2023.166942_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2016.00517","volume":"10","author":"Hiroi","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bbadis.2023.166942_bb0135","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0269881117725915","article-title":"Serotonin and brain function: a tale of two receptors","volume":"31","author":"Carhart-Harris","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bbadis.2023.166942_bb0140","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/0306-4522(91)90043-N","article-title":"Distribution, morphology and number of monoamine-synthesizing and substance P-containing neurons in the human dorsal raphe nucleus","volume":"42","author":"Baker","year":"1991","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbadis.2023.166942_bb0145","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/cn300127h","article-title":"Chronic SSRI treatment exacerbates serotonin deficiency in humanized Tph2 mutant mice","volume":"4","author":"Siesser","year":"2013","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.bbadis.2023.166942_bb0150","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.euroneuro.2018.07.099","article-title":"Serotonin transporter occupancy by the SSRI citalopram predicts default-mode network connectivity","volume":"28","author":"Schrantee","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bbadis.2023.166942_bb0155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1385\/MN:21:3:137","article-title":"The augmentation hypothesis for improvement of antidepressant therapy: is pindolol a suitable candidate for testing the ability of 5HT1A receptor antagonists to enhance SSRI efficacy and onset latency?","volume":"21","author":"Kinney","year":"2000","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bbadis.2023.166942_bb0160","first-page":"81","article-title":"Antidepressants, stressors and the serotonin 1A receptor","volume":"17","author":"Kirilly","year":"2015","journal-title":"Neuropsychopharmacol. Hung."},{"key":"10.1016\/j.bbadis.2023.166942_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2018.05.027","article-title":"5-HT6 receptor agonist and memory-enhancing properties of hypidone hydrochloride (YL-0919), a novel 5-HT1A receptor partial agonist and SSRI","volume":"138","author":"Chen","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbadis.2023.166942_bb0170","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3233\/JAD-200401","article-title":"Escitalopram alleviates Alzheimer's disease-type Tau pathologies in the aged P301L Tau transgenic mice","volume":"77","author":"Wang","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbadis.2023.166942_bb0175","doi-asserted-by":"crossref","first-page":"6744","DOI":"10.1523\/JNEUROSCI.14-11-06744.1994","article-title":"Distinct regulatory pathways control neurofilament expression and neurotransmitter synthesis in immortalized serotonergic neurons","volume":"11","author":"White","year":"1994","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2023.166942_bb0180","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1006\/exnr.1996.0121","article-title":"Autocrine BDNF secretion enhances the survival and serotonergic differentiation of raphe neuronal precursor cells grafted into the adult rat CNS","volume":"140","author":"Eaton","year":"1996","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbadis.2023.166942_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105973","article-title":"Mitophagy enhancers against phosphorylated Tau-induced mitochondrial and synaptic toxicities in Alzheimer disease","volume":"174","author":"Kshirsagar","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbadis.2023.166942_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102182","article-title":"MicroRNA-455-3p improves synaptic, cognitive functions and extends lifespan: relevance to Alzheimer\u2019s disease","volume":"48","author":"Kumar","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.bbadis.2023.166942_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/cells10113113","article-title":"RALBP1 in oxidative stress and mitochondrial dysfunction in Alzheimer's disease","volume":"10","author":"Awasthi","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bbadis.2023.166942_bb0200","first-page":"1856","article-title":"Adenovirus 36 improves glycemic control and markers of Alzheimer\u2019s disease pathogenesis","author":"Hegde","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"key":"10.1016\/j.bbadis.2023.166942_bb0205","article-title":"Protective effects of mitophagy enhancers against amyloid beta-induced mitochondrial and synaptic toxicities in Alzheimer disease","volume":"423-439","author":"Kshirsagar","year":"2022","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2023.166942_bb0210","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2990.2000.00254.x","article-title":"Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes","volume":"26","author":"Chen","year":"2000","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.bbadis.2023.166942_bb0215","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40478-023-01546-5","article-title":"Human tau-overexpressing mice recapitulate brainstem involvement and neuropsychiatric features of early Alzheimer's disease","volume":"11","author":"Khan","year":"2023","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.bbadis.2023.166942_bb0220","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pneurobio.2016.04.001","article-title":"Monoaminergic neuropathology in Alzheimer's disease","volume":"151","author":"\u0160imi\u0107","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.bbadis.2023.166942_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0197-4580(02)00057-X","article-title":"Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis","volume":"24","author":"Lyness","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbadis.2023.166942_bb0230","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neulet.2015.03.064","article-title":"5-HT1B and other related serotonergic proteins are altered in APPswe mutation","volume":"594","author":"Tajeddinn","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbadis.2023.166942_bb0235","doi-asserted-by":"crossref","first-page":"12841","DOI":"10.3390\/ijms232112841","article-title":"Phosphorylated tau in Alzheimer\u2019s disease and other tauopathies","volume":"23","author":"Rawat","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2023.166942_bb0240","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1073\/pnas.0711496105","article-title":"Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency","volume":"105","author":"Beaulieu","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2023.166942_bb0245","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/sj.npp.1300439","article-title":"In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain","volume":"29","author":"Li","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbadis.2023.166942_bb0250","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00401-002-0657-y","article-title":"Role of protein kinase B in Alzheimer's neurofibrillary pathology","volume":"105","author":"Pei","year":"2003","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbadis.2023.166942_bb0255","first-page":"1078","article-title":"Is Alzheimer\u2019s disease a type 3 diabetes? A critical appraisal","volume":"2017","author":"Kandimalla","year":"1863","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.bbadis.2023.166942_bb0260","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1517\/14728222.12.10.1265","article-title":"Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of type 2 diabetes","volume":"12","author":"MacAulay","year":"2008","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bbadis.2023.166942_bb0265","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1006\/mcne.1996.0016","article-title":"CNTF induces raphe neuronal precursors to switch from a serotonergic to a cholinergic phenotype in vitro","volume":"7","author":"Rudge","year":"1996","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.bbadis.2023.166942_bb0270","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0169-328X(98)00096-5","article-title":"Amyloid beta neurotoxicity in the cholinergic but not in the serotonergic phenotype of RN46A cells","volume":"57","author":"Olesen","year":"1998","journal-title":"Mol. Brain Res."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443923003083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443923003083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T19:02:50Z","timestamp":1738436570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443923003083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0925443923003083"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2023.166942","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protective effects of SSRI, Citalopram in mutant APP and mutant Tau expressed dorsal raphe neurons in Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2023.166942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"166942"}}